TD Cowen initiated coverage of Nkarta with a Buy rating and no price target. Nkarta is focused on the development of engineered natural killer cell therapies, the analyst tells investors in a research note. The firm says the company's lead candidate NKX019 is a CD19 CAR NK in two Phase I trials in a range of autoimmune diseases where it has the potential to meaningfully advance the standard of care. TD expects Nkarta to create "much long-term shareholder value" as NKX019 advances through clinical development.
